Enicepatide

Enicepatide (CT-388)

Evidence & Status

  • Moderate

Overview

Enicepatide (CT-388) is an investigational, once-weekly peptide-based dual agonist of the GLP-1 and GIP receptors being studied for obesity and related metabolic conditions. Published work describes cAMP-biased signaling at both receptors, with minimal beta-arrestin recruitment and receptor internalization in experimental systems. It is not FDA-approved.

Research Summary

A randomized, double-blind, placebo-controlled Phase 1 study evaluated once-weekly subcutaneous CT-388 in participants with obesity. The publication reported early weight-loss and glycemic findings, human pharmacokinetics supporting weekly administration, and a generally well-tolerated profile in which most treatment-emergent adverse events were mild or moderate. These findings do not establish long-term safety or clinical benefit.

Research Areas

  • Weight management
  • Metabolic research
  • GLP-1/GIP receptor signaling
United States
Investigational; not FDA-approved
United Kingdom
Current authorization status not established in this record.
Australia
Current authorization status not established in this record.
Canada
Current authorization status not established in this record.

Citations & Sources